Concussion – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Concussion Market Outlook

Thelansis’s “Concussion Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Concussion treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Concussion Overview

A concussion results from a traumatic impact, causing temporary brain function disturbance. It falls under traumatic brain injuries, which range from mild, brief symptoms to prolonged altered consciousness. The injury can stem from direct head impact or indirect forces affecting the brain due to body trauma. Common Concussion Symptoms include Confusion, Headache, Vision issues (blurriness, double vision), Dizziness or imbalance, Nausea or vomiting, Memory lapses, and Ringing in the ears. The underlying mechanism of a concussion is intricate, involving neurochemical and neurometabolic changes rather than just physical damage. Axonal injury from head movement disrupts neurofilament arrangement, releasing electrolytes and neurotransmitters that lead to neurologic dysfunction. Metabolic shifts and reduced cerebral blood flow also contribute. Concussion treatment focuses on support, beginning with reduced physical and cognitive activity and gradual reintegration. Initial diagnosis should consider severe possibilities like spinal injury, intracranial bleeding, or skull fractures. Post-injury, the prognosis is favorable, with symptoms improving within weeks. A complication is post-concussion syndrome (PCS), showing prolonged symptoms. Annually, the USA sees over 300,000 sports-related concussions, particularly prevalent in contact sports. The risk of experiencing a concussion in contact sports can be as high as 19% per year. High school contact sports alone report 62,000 concussions yearly. College football players show 34% with one and 20% with multiple concussions. Estimates suggest that 4-20% of college and high school football players acquire brain injuries in a single season, with a higher risk after a previous concussion.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: